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Summary Increased expression of the mdrl gene, encoding the 175 kDa P-glycoprotein, and the gst-r gene,
encoding the anionic isozyme of glutathione S-transferase (GST), have previously been detected in continuous
human breast cancer cell lines selected in vitro for resistance to doxorubicin. In this present study we have
measured RNA levels of mdrl and gst-s in primary human breast tumour biopsies prior to chemotherapy and
from tumours which have different inherent responses to doxorubicin treatment, including colon, head and
neck squamous cell carcinomas and myeloid leukaemias. Detectable levels of mdrl mRNA was observed in 25
out of 49 breast tumours, with up to a 100-fold range in expression. A narrower range of gst-s expression has
also been observed in these tumours. Chemosensitivity of cells grown in short-term culture from some of the
breast tumours has been measured by an in vitro colony forming assay in the presence of doxorubicin.
Comparison of the dose of doxorubicin causing 50% inhibition of growth (ID,,,) with RNA levels showed that
the tumours with high mdrl expression had high ID50, while the more sensitive explants had low mdrl
expression. These results support a role for mdrl gene expression in determining the response of human breast
cancer cells to chemotherapy.
Doxorubicin is known to be active against a range of solid
tumours and is one of the best available agents in the treat-
ment of breast cancer (Bonadonna et al., 1970; O'Bryan et
al., 1973; Blum & Carter, 1974). However, both inherent and
acquired resistance are in many cases major obstacles in
successful treatment (O'Bryan et al., 1977). Increased levels
of expression of the mdrl gene, which codes for a 175 kDa
plasma membrane associated glycoprotein, and the gst-rc
gene, encoding the anionic isozyme of glutathione S-
transferase (GSTh) have previously been shown in doxo-
rubicin (adriamycin) resistant cell lines, derived by drug selec-
tion in culture (Kartner et al., 1985; Riordan et al., 1985;
Scotto et al., 1986; Cowan et al., 1986; Deffie et al., 1988;
Van der Bliek et al., 1988). Many of these cell lines have been
shown to be cross resistant to other chemotherapeutic agents
such as Vinca alkaloids, anthracyclines and epipodophyl-
lotoxins and have been termed multidrug resistant (MDR).
The 175 kDa plasma membrane-associated protein, P-
glycoprotein, has been suggested to increase resistance to a
variety of drugs by increasing their efflux from the cell (Ger-
lach et al., 1986; Chen et al., 1986). GST isozymes have in
common the ability to catalyse conjugation of drugs to
reduced glutathione leading to drug detoxification (Jakoby,
1978).
A range of expression of mdr and gst-it has been shown in
human tumour samples, both between tumours derived from
different tissues and derived from the same tissue (Goldstein
et al., 1989; Gerlach et al., 1987; Moscow et al., 1989).
However, the relationship between levels of expression of
mdrl or gst-rc and clinical drug resistance has yet to be fully
elucidated. The identification of particular mechanisms of
resistance in a tumour type is important for treatments
designed to circumvent resistance (Kaye, 1988). In this pres-
ent study we have measured RNA levels ofmdri and gst-ir in
untreated human breast tumour biopsies. We have compared
the expression of these genes in breast cancer with other
tumour types including colon tumours, head and neck
squamous cell carcinomas and leukaemias, as well as cell
lines selected for resistance to doxorubicin. We have also
analysed epithelial cells grown during short term culture of
breast tumour biopsies for in vitro sensitivity to doxorubicin,
as measured by a colony forming assay (Smith et al.,
1981a,b). The response of cells to doxorubicin compared to
mdrl ahd gst-i mRNA allows an indirect analysis of whether
these mechanisms are involved in response of breast tumour
cells to doxorubicin.
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Materials and methods
RNA extractionfrom tumour biopsies
Tumour biopsies were frozen in liquid nitrogen immediately
after surgical removal and were stored frozen at - 70°C. All
solid tumour samples were from patients who had not
received any chemotherapy. Routine histology of the samples
confirmed that the majority of the biopsy consisted of
tumour cells. Solid tumours were pulverised whilst still frozen
in a micro-dismembrator II (Braun, FRG) and DNA and
RNA extracted by cell lysis and phenol/chloroform extrac-
tion (Kreig et al., 1983). Nucleated cells were isolated from
the leukaemic samples by ficoll gradient centrifugation and
RNA/DNA isolated as described above. DNA was removed
from the samples by digestion with RNase-free DNase I
(BCL, molecular biology grade). The quantity and quality of
the RNA was initially assessed by the presence of ribosomal
28S and 18S RNA after electrophoresis in agarose.
Hybridisation probes
An mdrl probe, mdr5A, which encodes about one-third of
the coding region of a full-length mdrl cDNA has previously
been described (Ueda et al., 1987b). One tLg of BamHl
digested mdr5A was used as substrate for a riboprobe tran-
scription kit (BCL) in the presence of uridine 5' a-32P-
triphosphate (30 TBq mmol-') from Amersham and SP6
polymerase. A full-length cDNA ofgst-in, pGPi (Kano et al.,
1987), was cloned into the EcoRI site of the polylinker ofthe
riboprobe vector Bluescribe (Pharmacia). One fg of HindIII
digested pGPi probe was used as substrate for riboprobe
transcription as described above. The 7S probe (Balmain et
al., 1982) was labelled with cytosine 5' x-32P-triphosphate
(111 TBq mmol ') from Amersham by nick translation and
Poly d(T) probe was made by kinase labelling poly d(T)18 20
oligonucleotide (Pharmapa) with adenosine 5' y-32P-triphos-
phate (111 TBq mmol'Jfrom Amersham.
Hybridisation analysis
Northern hybridisation The RNA was electrophoresed in
1.4% agarose/6% formaldehyde gels and transferred to Gene
Screen membranes (NEN/DuPont). Hybridisation was in
50% formamide buffer as previously described (Shen et al.,
1986) for 16 h at 57°C with 5 x 106 c.p.m. of synthetic RNA
per ml. The filters were washed with 2 x SSC/0.1% SDS for
15 min at room temperature followed by two 20 min washes
at 65°C with 0.1 x SSC/0.1% SDS. Autoradiograms were
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exposed for 1-3 days. Amounts of RNA on the filters were
quantified by reprobing the same filter with a probe for 7S
RNA and intensity of signal measured by densitometrical
scanning.
Dot blot hybridisation Gene screen filters were presoaked in
0.25 M di-sodium phosphate buffer and 15, 5, 1.6 and 0.5lag
of total RNA applied. After baking, prehybridisation, hy-
bridisation and washing were performed exactly as described
above for the Northern hybridisation experiments. Amounts
of RNA on the filters were quantified by reprobing the same
filter with a kinase labelled poly d(T) oligomer as previously
described (Harley, 1987). Repeat identical RNA from
tumours, MDR cell lines and their parental drug sensitive
cell lines which had a range of both mdrl and gstn expression
were analysed on all filters to allow comparison between
experiments. Autoradiograms were exposed overnight and
intensity of signals were quantified using densitometrical
scanning.
Colonyforming assayfor doxorubicin sensitivity ofbreast
tumour outgrowths
Sensitivity of breast cells to doxorubicin was assessed using
the short-term colony forming assay described by Smith et al.
(1981b, 1985). Tumour tissue was minced and disaggregated
in medium containing 200 Upl` collagenase (Worthington).
Resultant ductal alveolar structures and clumps of cells were
plated onto plastic and allowed to grow for 7-10 days.
Growth was supported in nutrient medium F10/DMEM sup-
plemented with 10-9 M oestradiol, 10jg ml-' insulin,
5fig ml-' transferin and 5 mg ml-' epidermal growth factor.
Outgrowth cells were then trypsinised, counted and plated
onto mitomycin C (4 mg ml-') treated STO mouse fibroblast
feeder layers. They were then exposed to a range of eight
concentrations of doxorubicin (from 5 x 10-6 M to
3.4 x 10- M) for 24 h. Drug was removed, the nutrient
medium replaced and surviving colonies counted after 2
weeks. Sensitivity was determined by the amount of drug
required to kill 50% of the control untreated cells (ID50).
Greater detail of this assay and analysis of a large number of
breast tumours will be published separately (S. Stallard, in
preparation).
Results
mdrl mRNA levels in human tumours
RNA prepared from human tumours and cell lines were
analysed by dot-blot hybridisation using the same conditions
of stringency that detect specific 4.5 kb mdrl mRNA tran-
scripts and 0.7 kb gst-i transcripts in Northern hybridisa-
tions. Typical dot-blots and Northern hybridisations using
each probe are shown in Figure 1. Of 49 primary breast
tumour biopsies from untreated patients, 25 samples had
measurable levels of mdrl mRNA (Figure 2). High levels of
mdrl mRNA were also detected in one breast tumour lymph
node biopsy. The levels of mdrl mRNA in some of these
tumours reached levels equivalent to that detected in cell
linesselectedfordrugresistancein vitro. Signalintensityof20fig
RNA from the cell lines MCF-7ADR (Cowan et al., 1986),
A2780AD (Rogan et al., 1984) and H69LX1O (an adriamycin
resistant cell line isolated from a human lung cell line; P.
Twentyman, personal communication) had values of 90, 160
and 100 respectively. Dot blot hybridisations contained
RNAs from the adriamycin resistant cell line, H69LX1O and
the parental drug sensitive line, H69, as well as repeat sam-
ples of the tumour RNAs to allow comparison between
hybridisation experiments as described in the Materials and
methods. Undetectable and very low signal intensities were
given an arbitrary value of 1.
Biopsy samples from untreated colon tumours all showed
detectable mdrl mRNA. The range of mdrl levels in the
colon tumours overlapped with about 20% of the breast
mdr
1 2 3 4 5 6 1 2
4.5 Kb -
c
1:2 |
Dilutions
gst-7
3 45 fi
- 0.7 Kb
a b c d e f g h i j k I
mdr
gst-
polyd(T)
Figure 1 Expression of mdrl and gst-r in cell lines and tumour
biopsies. a, Northern blot filter of cell line RNAs hybridised with
labelled mdr5A probe, showing specific mdrl 4.5 kb mRNA.
Sizes were determined by running in parallel molecular mass
markers from an RNA ladder (Bethesda Research Laboratories).
Lanes 2, 4 and 6 are adriamycin resistant cell lines H69LX1O,
MCF7ADR and A2780AD; lanes 1, 3 and 5 are the correspond-
ing parental cell lines. b, The filter shown in A was stripped of
hybridising probe and rehybridised with labelled GPi probe,
showing specific gst-i 0.7 kb mRNA. The filter was then re-
probed with 7S RNS probe to show equivalent loading of samp-
les (data not shown). c, Dot-blot hybridisation of tumour RNAs
probed with mdr5A, GPi and poly d(T). Lane a is H69LXIO,
lane, b-I are breast tumour RNAs.
tumour samples. Of fourteen untreated squamous cell car-
cinomas of the head and neck, eight had measurable levels of
mdrl mRNA. Detectable mdrl mRNA was also present in
three out of five untreated acute myeloid leukaemia (AML)
samples. The chronic myeloid leukaemia (CML) samples
shown represent sequential samples from the same patient.
The sample with undetectable mdrl RNA was taken prior to
chemotherapy, while the sample with detectable expression
was taken after anthracycline based chemotherapy.
gst-ic mRNA levels in human tumours
Figure 3 shows the gst-¶c mRNA levels detected in the same
tumour samples as shown in Figure 2. Signal intensity of
20 Lg RNA from the cell lines MCF-7ADR (Cowan et al.,
1986), A2087AD (Rogan et al., 1984) and H69LX1O (an
adriamycin resistant cell line isolated from a human lung cell
line; P. Twentyman, personal communication) had values of
60, 55 and 10 respectively. Dot blot hybridisations contained
RNAs from the adriamycin resistant cell line, H69LXIO and
the parental drug sensitive line, H69, as well as repeat sam-
ples of the tumour RNAs to allow comparison between
hybridisation experiments as described in the Materials and
methods. Undetectable and very low signal intensities were
given an arbitrary value of 1. All the breast tumour samples,
with the exception of one, showed low or undetectable levels
ofgst-ic mRNA. On the other hand all of the colon tumours,
with the exception of one, showed relatively high levels of
transcripts. The leukaemia samples generally had low levels
ofgst-i, including the sequential CML samples taken during
chemotherapy. A large proportion of squamous cell car-
cinomas of the head and neck had high levels of gst-¶c
mRNA levels.714 W.N. KEITH et al.
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Figure 2 Quantitation of mdrl expression in tumour samples.
Results obtained by dot-blot hybridisation with the mdr5A probe
are graphically displayed. Inverted triangles, untreated breast
tumours (filled symbols are lymph node biopsies); diamonds,
colon tumours; squares, squamous cell carcinomas of the head
and neck; open triangles, acute myeloid leukaemia; filled tri-
angles, chronic myeloid leukaemia. Undetectable and low levels
of mdrl expression are given an arbitrary value of 1. Adriamycin
resistant cell lines MCF7ADR, A2780AD and H69LXIO have
values of 90, 160 and 100 respectively on this scale.
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Figure 3 Quantitation of gst-i expression in tumour samples.
Results obtained by dot-blot hybridisation with the GPi probe
are graphically displayed. Symbols are as in Figure 2. Undetect-
able and low levels of gst-i expression are given an arbitrary
value of 1. Adriamycin resistant cell lines MCF7ADR, A2780AD
and H69LXIO have values of 60, 55 and 10 respectively on this
scale.
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Figure 4 mdrl and gst-i RNA levels and in vitro chemosen-
sitivity of breast tumours explants. RNA levels are as described
in Figures 2 and 3. The IDm of each sample is the concentration
of doxorubicin giving 50% surviving colonies of epithelial cell
outgrowths from breast tumour biopsies.
mdrl and gst-i may be occurring, as has been observed for
adriamycin resistant MCF7 breast cell lines (Cowan et al.,
1986).
Comparison ofmdrl and gst-7 mRNA levels to in vitro
sensitivity ofcell outgrowths ofbreast tumours
Comparison of doxorubicin IDm to mdrl and gst-7c mRNA
level is shown in Figure 4 for 14 breast tumour biopsies and
two normal breast tissue biopsies. No sample which is
relatively sensitive to doxorubicin was observed to have high
mdrl or gst-7c mRNA level. All of the samples with high
mdrl levels have relatively high ID50 for doxorubicin. The
level of mdrl expression weakly correlates with IDs to doxo-
rubicin with a Pearson correlation coefficient (r) of 0.46
(P <0.1). These observations support a role of mdrl expres-
sion in response of epithelial cells derived from breast
tumours to doxorubicin.
No significant correlation between IDo to doxorubicin and
gst-ic expression using the Pearson correlation test was
observed. Each individual tumour sample has been numbered
in Figure 4 to allow comparison between mdrl and gst-ic
expression. Sample number 13 showed high levels of mdrl
and gst-1 expression. Comparison between mdrl and gst-7
mRNA levels in all the breast samples assayed shows a low
level of correlation which is only slightly significant (r = 0.48,
P <0.1). Thus for some of these tumours coexpression of
Discussion
Doxorubicin is widely used in the treatment of advanced
breast cancer, with an overall response rate among breat
cancer patients ofabout 55% (Blum & Carter, 1974; O'Bryan
et al., 1977). This means that almost half the patients are
resistant to doxorubicin from the outset of treatment. A
better understanding of the mechanisms underlying this resis-
tance should lead to improved therapeutic results. Drug
delivery studies in breast cancer patients suggest that defec-
tive delivery of adriamycin into breast tumours is unlikely to
be a major factor (Stallard et al., 1990). Increased mdr and
gst-i expression have been detected in continuous human
breast cancer cell lines selected in vitro for resistance to
doxorubicin (Cowan et al., 1986; Moscow et al., 1988).
Several lines of evidence support the involvement of mdrl
expression in resistance of tumours to chemotherapy: (a)
full-length cDNAs for the mdrl gene transfected (Ueda et al.,
1987a) or infected (Guild et al., 1988) into cells confer multi-
drug resistance; (b) tumour types which are clinically drug
resistant, such as colon, generally have elevated mdrl mRNA
levels (Goldstein et al., 1989; Fojo et al., 1987b); (c) cell lines
from tumours with elevated mdrl mRNA levels have a multi-
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drug resistant phenotype which is reversible by inhibitors of
the multidrug transporter such as verapamil and quinidine
(Fojo et al., 1987a); (d) immunocytohistochemical staining
for P-glycoprotein expression correlates with in vitro sen-
sitivity to doxorubicin of tumour tissue from patients
(Salmon et al., 1989).
We have detected mdrl mRNA in 25 out of 49 primary
breast tumour biopsies from untreated patients. Detectable
mdrl expression has also been observed in one out of three
lymph node biopsies. In these untreated tumours a hundred
fold range in expression of mdrl has been observed with
some samples reaching the levels observed in resistant cell
lines selected in vitro. Levels of mdrl expression in about
20% of the breast tumour samples are equivalent to the
levels we detect in intrinsically chemoresistant colon tumours.
These results support a possible involvement of mdrl expres-
sion in response to chemotherapy of some breast tumours.
In vitro chemosensitivity to doxorubicin of epithelial cells
grown from breast tumour biopsies showed that no sample
which is relatively sensitive to doxorubicin was observed to
have high mdrl or gst-i mRNA level. All of the samples with
high mdrl levels have relatively high IDs for doxorubicin.
These observations are supportive of a role for mdrl expres-
sion in limiting the response of breast cells to doxorubicin. A
number of tumour samples however are relatively resistant to
doxorubicin, yet have low levels of mdrl expression. In these
tumours alternative resistance mechanisms may be effective.
Increased expression of gst-i, co-expressed with mdrl, has
been observed in some doxorubicin resistant breast tumour
cells (Cowan et al., 1986). With one exception, we have
detected low levels of gst-x mRNA in the breast tumour
samples. No large differences in expression levels were
detected and no significant correlation with doxorubicin sen-
sitivity of outgrowths was observed. However, it is still pos-
sible that gst-r expression may have a role in chemorespon-
siveness of a subset of breast tumours. A weak correlation
exists between expression of mdrl and gst-n in the breast
tumour samples we have analysed, suggesting that common
mechanisms may be involved in their expression.
Our results show that mdrl expression can be detected in
approximately half of the breast tumours analysed and that
explants from tumours with high mdrl expression are
relatively more resistant to doxorubicin in vitro. These results
are in agreement with those of Salmon et al. (1989), who
recently showed that five out of 13 breast tumours stained
positively with a P-glycoprotein antibody and that all five of
these tumours were 'resistant' using a short-term in vitro
assay of doxorubicin sensitivity. Goldstein et al. (1989) have
found detectable levels of mdrl mRNA in nine of 57 un-
treated breast tumour biopsies. However, Merkel et al. (1989)
found no mdrl mRNA in 53 untreated breast tumour sam-
ples. The differences in proportions of tumours with detect-
able mdrl mRNA may be due to technical variations in
sensitivity of the hybridisation conditions used. The stringent
hybridisation conditions used in this present study detect
only the mdrl specific 4.5 kb mRNA and appropriate
positive and negative control RNAs were included in hy-
bridisation experiments. However, the differences in detection
of mdrl mRNA may also represent variations in mdrl ex-
pression in tumours from different geographical locations.
Exposure to carcinogens has been shown in animal model
carcinogenesis systems to affect levels of mdr expression
(Gottesman, 1988). Differences in proportions of tumours
with detectable mdr expression may reflect variations in
tumour aetiology and carcinogen exposure in different geo-
graphical locations. We have also detected mdrl expression
in squamous cell carcinomas of the head and neck and in
samples from AML patients. All of these samples were from
patients who had not received chemotherapy.
Direct evidence for involvement of mdrl expression in
clinical response of tumours to chemotherapy would require
a prospective clinical trial. Drug resistance in multidrug re-
sistant cell lines can be overcome in vitro using agents such as
verapamil and quinidine which are thought to act by com-
petitively binding to the P-glycoprotein (Safa, 1988). High
expression of P-glycoprotein in breast tumours suggest that
trials using such reversing agent in conjunction with
chemotherapy may be appropriate for breast cancer. For
some drugs, such as quinidine, the levels which are clinically
achievable are equivalent to those which are effective in vivo
and a controlled clinical trial in breast cancer using quinidine
is underway in our department.
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